



**Today's CT
environment
demands
efficient
workflows.
Meet the
challenge with
MEDRAD Salient**




MEDRAD® Salient
Contrast Injection System

MEDRAD® Salient CT Injection System

Brings innovation and value to CT suites by combining mobility, simplicity and reliability.

Key Benefits:



Simplify your day



Control at your finger tips



Maximise your mobility



Take control



Rely on quality



Inject with flexibility




● Simplify your day



● Control at your finger tips



● Maximise your mobility



Take control

Protocol management is at your finger tips.

The remote control unit offers Wi-Fi remote control functionality which keeps you connected in and out of the scan room. Enjoy the flexibility to program injection protocols and manage the injector to enhance your work-flow.



Rely on quality

Proudly meeting all required international standards.

With thousands of units installed world wide, Salient is a proven, reliable injection system ensuring the highest possible quality for you and your patients.



Inject with flexibility



Saline flush is available for all your imaging needs.

The dual syringe head configuration with ImaxiFlow (simultaneous contrast and saline injection) opens the opportunity to perform more complex injection protocols to stay up to date with the latest CT imaging examinations, helping you to deliver the correct diagnosis for your patients.

Protocol Assistance Tool (PAT)

Bayer supports your contrast injection needs and offers products to implement IDR-based protocols.

- By unlocking the power of the wireless MEDRAD® Salient Contrast Injection System, the PAT software empowers you to deliver customised contrast media protocols to the patient for many common CT examinations.



- Ultravist® works seamlessly with the MEDRAD® Salient Contrast Injection System and PAT software.
- PAT is pre-populated with Ultravist® 370 and 300 to add confidence and efficiency to your workflow.



MEDRAD Salient Contrast Injector Specifications Overview

Functional		Mechanical	
Maximum pressure	300 psi	Weight	26kg (Dual)
Flow rate	0.1 to 10 ml/s	Height	1315mm
Maximum volume	190 ml	Floor area	500 mm x 500mm
Multi-phase protocols	Up to six phases (Storage for 20 different named protocols)	No. of wheels	4 castors, all individually locking
Manual/Auto fill rate	Up to 10ml/s	Electrical	
Controls		Line voltage	100 – 230VAC
Base	Line power On/off switch	Line frequency	50/60Hz
Head	5.7” LCD touch screen	Battery operation	Dual batteries, sealed lead acid
	Arm button	Mains power operation	Simultaneous operation and battery charging
	On/off soft switch	Contrast heat maintainer	37°C +/- 4°C, 5W (one included)
Infrared remote control	Inject now/stop		

Ordering Details

Part Name	Part No.
Salient Dual Injector with Wireless Control Unit	DC009DW
Salient Single Injector with Wireless Control Unit	DC009SW
Syringe with Spike (Box of 50)	ZY6323
Syringe with Spike and single LPCT (Box of 50)	ZY6324
Syringe with QFT and single LPCT (Box of 50)	ZY6325
Single LPCT (Box of 50)	ZY5151
Dual LPCT (Box of 50)	ZY5152

ULTRAVIST® (iopromide)

INDICATIONS: ULTRAVIST is indicated for all angiographic and urographic examinations and for contrast enhancement in computerised tomography. ULTRAVIST 300 or 370 is indicated for use in contrast-enhanced mammography in adults to visualise known or suspected lesions of the breast as an adjunct to mammography (with or without ultrasound). ULTRAVIST 240 is additionally indicated for lumbar myelography in adults. **CONTRAINDICATIONS:** known hypersensitivity or previous reaction to iodinated contrast media or excipients, immediate repeat myelography. ULTRAVIST 300 and 370 are contraindicated for intrathecal use. **PRECAUTIONS:** anaphylactoid/hypersensitivity or other idiosyncratic reactions; pretesting/sensitivity testing is not recommended, evaluate potential risk of hypothyroidism in patients with known or suspected thyroid dysfunction, monitor thyroid function in neonates who have been exposed to ULTRAVIST; patients with CNS disorders, exercise caution in situations of reduced seizure threshold; patients with pronounced states of excitement, anxiety and pain; patients with significant cardiac disease or severe coronary artery disease; thromboembolic events; patients with severely impaired renal function, combined renal and hepatic disease, combined renal and cardiac disease, anuria or when large doses are administered; ensure adequate hydration status before i.v. or i.t. administration to minimise PC-AKI and especially in renally impaired patients; patients with known or suspected pheochromocytoma; intravascular use in patients with autoimmune disorders, myasthenia gravis, cerebral angiography or peripheral angiography; intrathecal use in patients with seizure history; not for use in thoracic, cervical or total columnar myelography, cerebral ventriculography or cisternography; paediatrics; pregnancy (Category B2); effects on diagnosis and treatment of thyroid disorders with thyrotropic radioisotopes; avoid driving or operating machinery for the first 24 h after administration. **INTERACTIONS WITH OTHER MEDICINES:** metformin; neuroleptics and antidepressants; beta-blockers; interleukin-2. **ADVERSE EFFECTS:** Common: dizziness, headache, dysgeusia, blurred/disturbed vision, chest pain/discomfort, hypertension, vasodilation, vomiting, nausea, pain, injection site reactions, feeling hot. Refer to full PI for a complete list. **DOSAGE AND ADMINISTRATION:** Dosage should be adapted to age, weight, clinical question, examination technique and region to be investigated. Can be used with single-use or multi-patient use injector system. Administration may be intravascular or intrathecal depending on clinical problem and region to be investigated. For intrathecal use in myelography, only ULTRAVIST 240 is recommended and allow at least 48 h before repeat examination. Refer to full PI for details. Based on PI dated 18 December 2023.

Please review the full Product Information before prescribing. Approved PI available at <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2020-PI-02293-1> or upon request from Bayer Australia Ltd, ABN 22 000 138 714, 875 Pacific Highway, Pymble NSW 2073, phone 1800 008 757.

® Registered trademark of the Bayer Group, Germany

Bayer reserves the right to modify the specifications and features described herein or to discontinue any product or service identified in this publication at any time without prior notice or obligation. Please contact your authorised Bayer representative for the most current information.

All patient data that appear in this document are fictitious. No actual patient information is shown.

Bayer, the Bayer Cross, MEDRAD, Salient and MEDRAD Salient are trademarks owned by and/or registered to Bayer in the U.S. and/or other countries. Other trademarks and company names mentioned herein are properties of their respective owners and are used herein solely for informational purposes. No relationship or endorsement should be inferred or implied.

© 2025 Bayer. This material may not be reproduced, displayed, modified or distributed without the express prior written consent of Bayer.



Radiology

Bayer Australia Ltd 875
Pacific Highway Pymble
NSW 2073 Australia
Phone: 1800 008 757
ABN: 22 000 138 714



Manufacturer

Imaxeon Pty Ltd
Unit 1, 38 – 46 South Street
Rydalmere, NSW 2116
Australia
Phone: +61 2 8845 4999
Fax: +61 2 8845 4936

Australian Sponsor

Imaxeon Pty Ltd
Unit 1, 38 – 46 South Street Rydalmere,
NSW 2116 Australia
Phone: +61 2 8845 4999
Fax: +61 2 8845 4936
Customer Service: 1800 633 723